

Pharmacotherapy Frontiers 2005



Saturday, April 16, 2005
7:30 am – 3:05 pm
Masur Auditorium
Clinical Center (Building 10)
National Institutes of Health
Bethesda, Maryland

7:30 – 8:15

Registration

8:15 – 8:25

Welcome

Robert DeChristoforo, MS

Acting Chief, Pharmacy Department, Clinical Center, NIH

8:25 – 8:30

Morning Session Introduction

Justine Harris, RPh

Unit Dose Supervisor, Inpatient Pharmacy, Clinical Center, NIH

8:30 – 9:20

Medical Management of Abnormal Uterine Bleeding

Alicia Armstrong, MD

Reproductive Biology and Medicine Branch, NICHD, NIH

9:20 – 10:10

Novel Drug-Delivery Approaches for Eye Diseases at the NIH

Michael Robinson, MD

Ophthalmology Attending, Chief, NEI Consult Services Section, NEI, NIH

10:10 – 10:40

Break

10:40 – 11:35

Prescription Drug Importation into the U.S.: Looking at the Risks and Benefits

Thomas J. McGinnis, RPh

Director of Pharmacy Affairs, Office of Policy and Planning, FDA

11:35 – 12:30

Lunch

12:30 – 12:35

Afternoon Session Introduction

Melinda M. Neuhauser, PharmD

Clinical Pharmacy Specialist, Infectious Diseases, NIH

12:35 – 1:25

Bitter Sweet: State of the Art Diabetes Treatment

Kristina Rother, MD

Senior Staff Clinical Investigator, Islet and Autoimmunity Branch, NIDDK, NIH

1:25 – 2:15

Update on Total Parenteral Nutrition (TPN) in the MICU

Brad Moriyma, PharmD

Clinical Pharmacy Specialist, Medical Intensive Care Unit, NIH

2:15 – 3:05

Targeted Cancer Therapy Utilizing Oral Tyrosine Kinase Inhibitors: Imatinib (Gleevec®), Gefitinib (Iressa®), Erlotinib (Tarceva®) and Beyond

Thomas Hughes, PharmD, BCOP

Clinical Pharmacy Specialist, Hematology/Oncology, NIH

The NIH Clinical Center Pharmacy Department is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program meets the ACPE criteria for six contact hours (0.6 CEUs) of continuing pharmacy education credit. Statements of Credit will be awarded within 60 days after the seminar to those who successfully complete the program. Successful completion requires evaluation of each session attended. The evaluation form must be completed online within one week of the program. This program is fully supported by the National Institutes of Health and has no other sponsor. ACPE

Universal Program numbers:

603-000-05-001-L01 (Uterine Bleeding)

603-000-05-004-L01 (Diabetes Treatment)

603-000-05-002-L01 (Eye Drug Delivery)

603-000-05-005-L01 (TPN)

603-000-05-003-L03 (Drug Importation)

603-000-05-006-L01 (Cancer Therapy)

